Key Takeaways
- Evogene Ltd. expands partnership with Google Cloud to integrate AI Agents into ChemPass AI™
- Collaboration leverages Google Cloud’s Vertex AI platform to enhance small-molecule discovery
- AI Agents designed to automate complex scientific workflows and accelerate design cycles
- Builds on October 2024 milestone involving a generative AI foundation model
- Expansion supports pharmaceutical and agricultural small-molecule development
Evogene Ltd. Advances ChemPass AI™ with Google Cloud AI Agents
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a computational chemistry company focused on AI-driven small-molecule design for pharmaceutical and agricultural applications, has announced an expanded phase of its collaboration with Google Cloud.
Under the new phase, Evogene Ltd. will develop and integrate advanced AI Agents into its ChemPass AI™ platform using Google Cloud’s Vertex AI infrastructure. The initiative aims to enhance the speed, precision, and efficiency of identifying and optimizing small molecules for drug and ag-chemical development.
This marks the second major milestone in the partnership between Evogene Ltd. and Google Cloud. In October 2024, the companies announced the successful development of a generative AI foundation model that now serves as a core component of ChemPass AI™.
4 Comments